Thrombodynamics test

Last updated
Thrombodynamics test
Purposemethod for blood coagulation monitoring and anticoagulant control

Thrombodynamics test is a method for blood coagulation monitoring and anticoagulant control. This test is based on imitation of coagulation processes occurring in vivo, is sensitive both to pro- and anticoagulant changes in the hemostatic balance. Highly sensitive to thrombosis.


The method was developed in the Physical Biochemistry Laboratory under the direction of Prof. Fazly Ataullakhanov.

Technology description

Thrombodynamics analyser scheme Metod trombodinamiki i tipichnye fotografii rosta sgustka.jpg
Thrombodynamics analyser scheme

Thrombodynamics designed to investigate the in vitro spatial-temporal dynamics of blood coagulation initiated by localized coagulation activator under conditions similar to the conditions of the blood clotting in vivo. Thrombodynamics takes into account the spatial heterogeneity trombodinamiki processes in blood coagulation. The test is performed without mixing in a thin layer of plasma.

The measurement cuvette with the blood plasma sample is placed inside the water thermostat. Clotting starts when activator with immobilized TF is immersed into the cuvette. The clot then propagates from the activating surface into the bulk of plasma. Image of growing clot is registered via the CCD camera using a time-lapse microscopy mode in scattered light and then parameters of coagulation are calculated on the computer. Thrombodynamics analyser T-2 device also supports measurement of spatial dynamics of thrombin propagation during the process of clot growth via usage of the fluorogenic substrate for thrombin. Blood plasma sample is periodically irradiated with the excitation light and the emission of the fluorophore is registered by CCD camera.

Mathematical methods are used to restore spatio-temporal distribution of the thrombin from the fluorophore signal. This experimental model worked well in research and has demonstrated good sensitivity to various disorders of the coagulation system.

[1] [2] [3] [4] [5] [6] [7]



See also

Related Research Articles

Coagulation Process by which blood changes from a liquid to a gel, forming a blood clot

Coagulation, also known as clotting, is the process by which blood changes from a liquid to a gel, forming a blood clot. It potentially results in hemostasis, the cessation of blood loss from a damaged vessel, followed by repair. The mechanism of coagulation involves activation, adhesion and aggregation of platelets, as well as deposition and maturation of fibrin.

Disseminated intravascular coagulation Medical condition

Disseminated intravascular coagulation (DIC) is a condition in which blood clots form throughout the body, blocking small blood vessels. Symptoms may include chest pain, shortness of breath, leg pain, problems speaking, or problems moving parts of the body. As clotting factors and platelets are used up, bleeding may occur. This may include blood in the urine, blood in the stool, or bleeding into the skin. Complications may include organ failure.

Fibrinolysis is a process that prevents blood clots from growing and becoming problematic. Primary fibrinolysis is a normal body process, while secondary fibrinolysis is the breakdown of clots due to a medicine, a medical disorder, or some other cause.


Antithrombin (AT) is a small protein molecule that inactivates several enzymes of the coagulation system. Antithrombin is a glycoprotein produced by the liver and consists of 432 amino acids. It contains three disulfide bonds and a total of four possible glycosylation sites. α-Antithrombin is the dominant form of antithrombin found in blood plasma and has an oligosaccharide occupying each of its four glycosylation sites. A single glycosylation site remains consistently un-occupied in the minor form of antithrombin, β-antithrombin. Its activity is increased manyfold by the anticoagulant drug heparin, which enhances the binding of antithrombin to factor IIa (Thrombin) and factor Xa.

Prothrombin time

The prothrombin time (PT) – along with its derived measures of prothrombin ratio (PR) and international normalized ratio (INR) – are assays evaluating the extrinsic pathway and common pathway of coagulation. This blood test is also called protime INR and PT/INR. They are used to determine the clotting tendency of blood, in such things as the measure of warfarin dosage, liver damage, and vitamin K status. PT measures the following coagulation factors: I (fibrinogen), II (prothrombin), V (proaccelerin), VII (proconvertin), and X.

Partial thromboplastin time Test for coagulation of the blood

The partial thromboplastin time (PTT) or activated partial thromboplastin time is a blood test that characterizes coagulation of the blood. A historical name for this measure is the kaolin-cephalin clotting time (KCCT), reflecting kaolin and cephalin as materials historically used in the test. Apart from detecting abnormalities in blood clotting, partial thromboplastin time is also used to monitor the treatment effect of heparin, a widely prescribed drug that reduces blood's tendency to clot.

Factor XIII

Factor XIII or fibrin stabilizing factor is a zymogen found from the blood of humans and some other animals. It is activated by thrombin to factor XIIIa. XIIIa is an enzyme of the blood coagulation system that crosslinks fibrin. Deficiency of XIII worsens clot stability and increases bleeding tendency.

Lupus anticoagulant is an immunoglobulin that binds to phospholipids and proteins associated with the cell membrane. Its name is a misnomer, as it is actually a prothrombotic antibody. Lupus anticoagulant in living systems cause an increase in inappropriate blood clotting. The name derives from their properties in vitro, as these antibodies increase laboratory coagulation tests such as the activated partial thromboplastin time (aPTT). Investigators speculate that the antibodies interfere with phospholipids used to induce in vitro coagulation. In vivo, the antibodies are thought to interact with platelet membrane phospholipids, increasing adhesion and aggregation of platelets, which accounts for the in vivo prothrombotic characteristics.

Protein S

Protein S is a vitamin K-dependent plasma glycoprotein synthesized in the liver. In the circulation, Protein S exists in two forms: a free form and a complex form bound to complement protein C4b-binding protein (C4BP). In humans, protein S is encoded by the PROS1 gene. Protein S plays a role in coagulation.

Thrombophilia Abnormality of blood coagulation

Thrombophilia is an abnormality of blood coagulation that increases the risk of thrombosis. Such abnormalities can be identified in 50% of people who have an episode of thrombosis that was not provoked by other causes. A significant proportion of the population has a detectable thrombophilic abnormality, but most of these develop thrombosis only in the presence of an additional risk factor.

Dilute Russells viper venom time

Dilute Russell's viper venom time (dRVVT) is a laboratory test often used for detection of lupus anticoagulant (LA).

The prothrombinase complex consists of the serine protease, Factor Xa, and the protein cofactor, Factor Va. The complex assembles on negatively charged phospholipid membranes in the presence of calcium ions. The prothrombinase complex catalyzes the conversion of prothrombin (Factor II), an inactive zymogen, to thrombin (Factor IIa), an active serine protease. The activation of thrombin is a critical reaction in the coagulation cascade, which functions to regulate hemostasis in the body. To produce thrombin, the prothrombinase complex cleaves two peptide bonds in prothrombin, one after Arg271 and the other after Arg320. Although it has been shown that Factor Xa can activate prothrombin when unassociated with the prothrombinase complex, the rate of thrombin formation is severely decreased under such circumstances. The prothrombinase complex can catalyze the activation of prothrombin at a rate 3 x 105-fold faster than can Factor Xa alone. Thus, the prothrombinase complex is required for the efficient production of activated thrombin and also for adequate hemostasis.

Tissue factor pathway inhibitor

Tissue factor pathway inhibitor is a single-chain polypeptide which can reversibly inhibit Factor Xa (Xa). While Xa is inhibited, the Xa-TFPI complex can subsequently also inhibit the FVIIa-tissue factor complex. TFPI contributes significantly to the inhibition of Xa in vivo, despite being present at concentrations of only 2.5 nM.

Thromboelastography (TEG) is a method of testing the efficiency of blood coagulation. It is a test mainly used in surgery and anesthesiology, although increasingly used in resuscitations in Emergency Departments, intensive care units, and labor and delivery suites. More common tests of blood coagulation include prothrombin time (PT) and partial thromboplastin time (aPTT) which measure coagulation factor function, but TEG also can assess platelet function, clot strength, and fibrinolysis which these other tests cannot.

Heparin cofactor II

Heparin cofactor II (HCII), a protein encoded by the SERPIND1 gene, is a coagulation factor that inhibits IIa, and is a cofactor for heparin and dermatan sulfate.

Purpura fulminans is an acute, often fatal, thrombotic disorder which manifests as blood spots, bruising and discolouration of the skin resulting from coagulation in small blood vessels within the skin and rapidly leads to skin necrosis and disseminated intravascular coagulation.

Carboxypeptidase B2

Carboxypeptidase B2 (CPB2), also known as carboxypeptidase U (CPU), plasma carboxypeptidase B (pCPB) or thrombin-activatable fibrinolysis inhibitor (TAFI), is an enzyme that, in humans, is encoded by the gene CPB2.

Thromboelastometry (TEM), previously named rotational thromboelastography (ROTEG) or rotational thromboelastometry (ROTEM), is an established viscoelastic method for hemostasis testing in whole blood. It is a modification of traditional thromboelastography (TEG). TEM investigates the interaction of coagulation factors, their inhibitors, anticoagulant drugs, blood cells, specifically platelets, during clotting and subsequent fibrinolysis. The rheological conditions mimic the sluggish flow of blood in veins. While traditional thromboelastography is a global assay for blood clotting disorders and drug effects, TEM is primarily used in combination with appropriate differential assays. They allow testing in the presence of therapeutic heparin concentrations and provide differential diagnostic information to support decisions in therapy. In numerous publications the validity of the method is shown. Application of TEM at the point of care (POC) or in emergency laboratories is getting more and more popular. TEM detects both hypo- and hyperfunctional stages of the clotting process and is probably the only reliable rapid test for the diagnosis of hyperfibrinolysis. In contrast to standard clotting tests, the fibrin stabilizing effect of factor XIII contributes to the result. The rapid availability of results helps to discriminate surgical bleeding from a true haemostasis disorder and improves the therapy with blood products, factor concentrates, anticoagulants and protamine, hemostyptic and antifibrinolytic drugs. Several reports confirm that application of TEM is cost effective by reducing the consumption of blood products.

Blood clotting tests are the tests used for diagnostics of the hemostasis system. Coagulometer is the medical laboratory analyzer used for testing of the hemostasis system. Modern coagulometers realize different methods of activation and observation of development of blood clots in blood or in blood plasma.

Acquired haemophilia A (AHA) is a rare but potentially life-threatening bleeding disorder characterized by autoantibodies directed against coagulation factor VIII. These autoantibodies constitute the most common spontaneous inhibitor to any coagulation factor and may induce spontaneous bleeding in patients with no previous history of a bleeding disorder.


  1. Soshitova NP, Karamzin SS, Fadeeva OA, et al. (2012). "Predicting prothrombotic tendencies in sepsis using spatial clot growth dynamics". Blood Coagul Fibrinolysis. 23 (6): 498–507. doi:10.1097/MBC.0b013e328352e90e. PMID   22688554. S2CID   5418128.
  2. Parunov LA, Fadeeva OA, Balandina AN, et al. (2011). "Improvement of spatial fibrin formation by the anti-TFPI aptamer BAX499: changing clot size by targeting extrinsic pathway initiation". Thromb. Haemost. 9 (Jun): 1825–34. doi:10.1111/j.1538-7836.2011.04412.x. PMID   21696535. S2CID   25911422.
  3. Ovanesov MV, Panteleev MA, Sinauridze EI, et al. (2008). "Mechanisms of action of recombinant activated factor VII in the context of tissue factor concentration and distribution". Blood Coagul. Fibrinolysis. 19 (8): 743–755. doi:10.1097/MBC.0b013e3283104093. PMID   19002040. S2CID   45231920.
  4. Ovanesov M.V.; Krasotkina J.V.; Ul’yanova L.I.; et al. (2002). "Hemophilia A and B are associated with abnormal spatial dynamics of clot growth". Biochim Biophys Acta. 1572 (1): 45–57. doi:10.1016/s0304-4165(02)00278-7. PMID   12204332.
  5. Ovanesov M.V.; Lopatina E.G.; Saenko E.L.; et al. (2003). "Effect of factor VIII on tissue factor-initiated spatial clot growth". Thromb Haemost. 89 (2): 235–242. doi:10.1055/s-0037-1613437. PMID   12574801.
  6. Ovanesov M.V.; Ananyeva N.M.; Panteleev M.A.; et al. (2005). "Initiation and propagation of coagulation from tissue factor bearing cell monolayers to plasma: initiator cells do not regulate spatial growth rate". J Thromb Haemost. 2 (3): 321–331. doi: 10.1111/j.1538-7836.2005.01128.x . PMID   15670039.
  7. Panteleev M.A.; Ovanesov M.V.; Kireev D.A; et al. (2006). "Spatial propagation and localization of blood coagulation are regulated by intrinsic and protein C pathways, respectively". Biophys. J. 90 (5): 1489–1500. Bibcode:2006BpJ....90.1489P. doi:10.1529/biophysj.105.069062. PMC   1367302 . PMID   16326897.